阿氯米松(Alclometasone Dipropionate) - 药物靶点：GR_在研适应症：皮炎，瘙痒，湿疹_专利_临床

概要

基本信息

药物类型

小分子化药

别名

Alclometasone、Alclometasone dipropionate (JAN/USP)

+ [11]

靶点

GR

作用机制

GR激动剂(糖皮质激素受体激动剂)

治疗领域

免疫系统疾病感染遗传病与畸形+ [3]

在研适应症

皮炎瘙痒湿疹+ [9]

非在研适应症

嗜皮菌病

原研机构

Fougera Pharmaceuticals, Inc.

在研机构

Shionogi & Co., Ltd.

Aspire Pharma Ltd.

非在研机构

Fougera Pharmaceuticals, Inc.

重庆华邦制药有限公司

最高研发阶段批准上市

首次获批日期

美国 (1982-12-14),

嗜皮菌病

最高研发阶段(中国)无进展

特殊审评-

登录后查看时间轴

结构

分子式C28H37ClO7

InChIKeyDJHCCTTVDRAMEH-DUUJBDRPSA-N

CAS号66734-13-2

关联

2

项与阿氯米松相关的临床试验

NCT01465802 / Completed临床2期

ARCHER 1042: A PHASE 2 STUDY OF DACOMITINIB IN ADVANCED NON-SMALL CELL LUNG CANCER (POST-CHEMOTHERAPY OR SELECT FIRST LINE PATIENTS) TO EVALUATE PROPHYLACTIC INTERVENTION ON DERMATOLOGIC AND GASTROINTESTINAL ADVERSE EVENTS AND PATIENT REPORTED OUTCOMES

To assess the impact of prophylactic treatment on the incidence of adverse events in advanced NSCLC patients (post chemotherapy) treated with dacomitinib daily as a single agent. To assess the impact of an interrupted dacomitinib dosing schedule in Cycle 1 on the incidence of adverse events in first-line advanced NSCLC patients with an EGFR mutation (HER-1 mutation, HER-2 mutation or HER-2 amplification).

开始日期2011-12-26

申办/合作机构

Pfizer Inc.

NCT02075632 / Completed临床2期

A Mult-Center, Open-Label Study to Evaluate Product Duration of Use Experience With Aclometasone Diproprionate Cream

This is a multi-center, open-label study to evaluate whether participants follow the duration of use instructions for short-term use of alclometasone dipropionate in a population of participants with itchy skin conditions who would use OTC treatments for relief. The study population will be composed of two different cohorts: chronic condition sufferers (eczema or psoriasis) and participants who suffer from occasional itchy skin experiences (such as poison ivy, oak, sumac, insect bites, or skin irritations due to jewelry, cosmetics, detergents, or soaps) where an anti-itch medication would be used.

开始日期2006-09-01

申办/合作机构

GSK Plc

100 项与阿氯米松相关的临床结果

登录后查看更多信息

100 项与阿氯米松相关的转化医学

登录后查看更多信息

100 项与阿氯米松相关的专利（医药）

登录后查看更多信息

35

项与阿氯米松相关的文献（医药）

2024-01-01·Traffic

Glucocorticoids rescue cell surface trafficking of R451C Neuroligin3 and enhance synapse formation

Article

作者: De Jaco, Antonella ; Comoletti, Davide ; Bianchi, Sara ; Miranda, Elena ; Trobiani, Laura ; Di Angelantonio, Silvia ; Sollazzo, Raimondo ; Lauro, Clotilde ; Giorda, Ezio ; Serafini, Federica ; Ragozzino, Davide ; Guglielmo, Stefano ; Perfetto, Camilla ; Ferrucci, Laura ; Diamanti, Tamara ; Gioia, Roberta ; Setini, Andrea ; Mautone, Lorenza ; Cacci, Emanuele

AbstractNeuroligins are synaptic cell adhesion proteins with a role in synaptic function, implicated in neurodevelopmental disorders. The autism spectrum disorder‐associated substitution Arg451Cys (R451C) in NLGN3 promotes a partial misfolding of the extracellular domain of the protein leading to retention in the endoplasmic reticulum (ER) and the induction of the unfolded protein response (UPR). The reduced trafficking of R451C NLGN3 to the cell surface leads to altered synaptic function and social behavior. A screening in HEK‐293 cells overexpressing NLGN3 of 2662 compounds (FDA‐approved small molecule drug library), led to the identification of several glucocorticoids such as alclometasone dipropionate, desonide, prednisolone sodium phosphate, and dexamethasone (DEX), with the ability to favor the exit of full‐length R451C NLGN3 from the ER. DEX improved the stability of R451C NLGN3 and trafficking to the cell surface, reduced the activation of the UPR, and increased the formation of artificial synapses between HEK‐293 and hippocampal primary neurons. The effect of DEX was validated on a novel model system represented by neural stem progenitor cells and differentiated neurons derived from the R451C NLGN3 knock‐in mouse, expressing the endogenous protein. This work shows a potential rescue strategy for an autism‐linked mutation affecting cell surface trafficking of a synaptic protein.

2021-01-01·Pediatric Dermatology4区 · 医学

Comparing prescribing patterns for topical corticosteroids based on their FDA indication by age

4区 · 医学

Article

作者: Cline, Abigail ; Feldman, Steven R. ; Fleischer, Alan B. ; Balogh, Esther A. ; Freeze, Megan E.

AbstractBackground/ObjectivesAtopic dermatitis (AD) affects up to 20% of the pediatric population, with a growing prevalence over the past 30 years. Topical corticosteroids (TCS) are commonly used as a first‐line topical therapy for AD and are prescribed in 59% of all AD visits. However, some topical corticosteroids are prescribed outside of their age range indications. This paper aims to explore the frequency with which topical corticosteroids are prescribed for AD outside of their FDA‐approved age range.MethodsData on prescribing patterns for AD were obtained from the National Ambulatory Medical Care Survey (NAMCS). We assessed the frequency of off‐label use of topical corticosteroids with respect to age indications in four specific age‐groups, as delineated in the data (0‐1, 2‐7, 8‐18, and 19+ years).ResultsAll prescribed topical corticosteroids found in the NAMCS database have an indication for AD or other inflammatory dermatoses or pruritic dermatoses. However, some medications were prescribed outside of their FDA‐approved age indications. These off‐label prescription rates ranged from 52% for desoximetasone to 0% for halobetasol and alclometasone, or rates lower than could be detected by our study.ConclusionsMuch like other medications for AD treatment, TCS are sometimes used off‐label. The off‐label use of topical corticosteroids to treat pediatric AD highlights a gap between clinical practice and regulating guidelines. Additional pediatric studies would offer a greater body of evidence to maintain or expand label indications for the use of TCS in younger patients.

2016-12-01·BMC Pharmacology and Toxicology

Side effect profile similarities shared between antidepressants and immune-modulators reveal potential novel targets for treating major depressive disorders

Article

作者: Wittenberg, Gayle M ; Narayan, Vaibhav A ; Sun, Yu

BACKGROUNDSide effects, or the adverse effects of drugs, contain important clinical phenotypic information that may be useful in predicting novel or unknown targets of a drug. It has been suggested that drugs with similar side-effect profiles may share common targets. The diagnostic class, Major Depressive Disorder, is increasingly viewed as being comprised of multiple depression subtypes with different biological root causes. One 'type' of depression generating substantial interest today focuses on patients with high levels of inflammatory burden, indicated by elevated levels of C-reactive proteins (CRP) and pro-inflammatory cytokines such as interleukin 6 (IL-6). It has been suggested that drugs targeting the immune system may have beneficial effect on this subtype of depressed patients, and several studies are underway to test this hypothesis directly. However, patients have been treated with both anti-inflammatory and antidepressant compounds for decades. It may be possible to exploit similarities in clinical readouts to better understand the antidepressant effects of immune-related drugs.METHODSHere we explore the space of approved drugs by comparing the drug side effect profiles of known antidepressants and drugs targeting the immune system, and further examine the findings by comparing the human cell line expression profiles induced by them with those induced by antidepressants.RESULTSWe found 7 immune-modulators and 14 anti-inflammatory drugs sharing significant side effect profile similarities with antidepressants. Five of the 7 immune modulators share most similar side effect profiles with antidepressants that modulate dopamine release and/or uptake. In addition, the immunosuppressant rapamycin and the glucocorticoid alclometasone induces transcriptional changes similar to multiple antidepressants.CONCLUSIONSThese findings suggest that some antidepressants and some immune-related drugs may affect common molecular pathways. Our findings support the idea that certain medications aimed at the immune system may be helpful in relieving depressive symptoms, and suggest that it may be of value to test immune-modulators for antidepressant-like activity in future proof-of-concept studies.

100 项与阿氯米松相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D01820	阿氯米松	D07AB10 S01BA10	DB00240

研发状态

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
皮炎	英国	Aspire Pharma Ltd.	1995-04-26
瘙痒	英国	Aspire Pharma Ltd.	1995-04-26
湿疹	日本	Shionogi & Co., Ltd.	1988-03-29
红斑	日本	Shionogi & Co., Ltd.	1988-03-29
昆虫咬伤和螫伤	日本	Shionogi & Co., Ltd.	1988-03-29
掌跖角化病	日本	Shionogi & Co., Ltd.	1988-03-29
扁平苔藓	日本	Shionogi & Co., Ltd.	1988-03-29
盘状红斑狼疮	日本	Shionogi & Co., Ltd.	1988-03-29
痒疹	日本	Shionogi & Co., Ltd.	1988-03-29
银屑病	日本	Shionogi & Co., Ltd.	1988-03-29
紫癜	日本	Shionogi & Co., Ltd.	1988-03-29
蔷薇疹病毒感染	日本	Shionogi & Co., Ltd.	1988-03-29

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT01465802 (ARCHER 1042, CTgov)	临床2期	晚期非小细胞肺癌	236	Placebo+Doxycycline+Dacomitinib (Cohort I: Arm A (Dacomitinib 45 mg + Doxycycline Placebo))	鹹選襯憲憲窪窪糧築觸(繭鬱齋窪膚網膚艱憲衊) = 淵廠鑰艱觸積願醖範顧壓夢願憲願選鹹獵壓夢 (網衊構蓋襯鬱範醖鬱壓, 鏇構積鹹蓋簾遞觸衊糧 ~ 餘觸廠蓋鑰餘獵齋製鬱) 更多	-	2016-08-17
				Doxycycline+Dacomitinib (Cohort I: Arm B (Dacomitinib 45 mg + Doxycycline 100 mg))	鹹選襯憲憲窪窪糧築觸(繭鬱齋窪膚網膚艱憲衊) = 鏇簾鑰夢餘窪糧衊願餘壓夢願憲願選鹹獵壓夢 (網衊構蓋襯鬱範醖鬱壓, 觸願構廠窪鹽淵夢構蓋 ~ 糧憲衊顧選繭壓遞齋夢) 更多
NCT01465802 (ARCHER 1042, WCLC2015)	临床2期	晚期非小细胞肺癌	112	Dacomitinib 45 mg + placebo	遞艱鑰壓鏇衊蓋鬱膚顧(築襯繭構齋蓋鹹鬱襯艱) = improved with prophylactic doxy, but not alclo; prophylactic probiotic was not associated with improved CTCAE or PRO 網蓋糧醖壓鏇網築觸顧 (蓋壓築選觸壓鏇顧齋鬱 )	-	2015-09-08
				Dacomitinib 45 mg + Doxycycline 100 mg